PLANO, TX & BALTIMORE, MD, USA I March 25, 2025 I Secretome Therapeutics, a clinical-stage biotechnology company developing novel therapies derived from ...

Systemic administration of Olvi-Vec in the initial dose escalation cohorts achieved a 71% disease control rate (5/7) with two partial responders. All ...

PARIS, France I March 25, 2025 I The US Food and Drug Administration (FDA) is evaluating under priority review the regulatory submission of tolebrutinib to ...

BEIJING, China I March 24, 2025 I SineuGene Therapeutics Co., Ltd. ("SineuGene"), a clinical-stage biotech company pioneering innovative therapies for ...

NANTONG, China and MELBOURNE, Australia I March 24, 2025 I Ractigen Therapeutics, a clinical-stage biopharmaceutical company pioneering small activating RNA ...

NEW YORK, NY, USA I March 24, 2025 I On March 17, 2025, US time, the world's first acute myocardial infarction (AMI) antibody drug, SGC001, developed by ...

GUANGDONG, China and BAGSVAERD, Denmark I March 24, 2025 IThe United Laboratories International Holdings Limited (TUL) and Novo Nordisk A/S (Novo Nordisk) ...

SHANGHAI, China I March 23, 2025 I Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, ...

U.S. IND clearance and revaccination trial initiation supports the differentiated global opportunity for Clover's RSV PreF vaccine (SCB-1019) ...

COAST Phase 3 trial failed to meet primary endpoint of mean change in BCVA from baseline to week 52. Opthea considering impact of negative trial results under its Development Fund ...

MELBOURNE, Australia and INDIANAPOLIS, IN, USA I March 21, 2025 I Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces ...

BEIJING, China I March 21, 2025 I Syneron Bio, a cutting-edge oral macrocyclic peptide drug biotech company, announced today a strategic collaboration with ...